Core Insights - The National Healthcare Security Administration (NHSA) has established a pricing mechanism for newly launched drugs and medical devices, specifically supporting the clinical application and pricing of brain-computer interface (BCI) technologies [1][2] - The introduction of standardized pricing for BCI services is expected to facilitate the adoption of these technologies in clinical settings, indicating that BCI technology is nearing clinical usability [3] Industry Developments - Over 100 new pricing items related to medical technologies have been added, including specific fees for invasive and non-invasive BCI procedures [1] - Provinces such as Jiangsu, Zhejiang, and Hubei have published their BCI service pricing, with fees for non-invasive BCI adaptation set at approximately 966 RMB per session, invasive BCI implantation at around 6,600 RMB, and extraction fees ranging from 3,139 to 3,200 RMB [2] - The NHSA's guidelines emphasize the integration of artificial intelligence in rehabilitation, setting a target for AI-assisted rehabilitation services to be implemented nationwide by 2025, which aligns with the development of BCI technologies [2] Market Potential - Analysts predict significant growth in the global BCI medical application market, estimating it could reach $40 billion by 2030 and $145 billion by 2040 [3] - The BCI industry in China is transitioning from laboratory research to commercial application, indicating a high growth potential and the need for long-term investment strategies focused on technology stability and production capabilities [3] Related Companies - MicroPort NeuroScience (02172) has achieved a significant market share in China's neuro-interventional medical device sector, ranking fourth based on 2023 sales revenue [4] - HeartVue Medical-B (06609) successfully completed animal trials for China's first interventional BCI, with expectations of turning a profit by mid-2025 [4] - Nanjing Panda Electronics (00553) is actively developing a multimodal human-computer interaction system based on BCI technology as part of a key provincial research project [4]

心玮医疗-B(6609.HK)今日盘中一度大涨11.84%至61.85港元，股价创2022年2月15日以来近3年半新高，年内累涨超1.8倍。 心玮医疗-B昨日晚间发公告称，截至2025年6月30日止六个月，集团预期录得股东应占净利润不少于人民币4000万元，较截至2024年6月30日止六个月录得的 股东应占净亏损约人民币510万元大幅转亏为盈。预期录得利润及业绩改善主要由于集团的业务增长，导致与相应期间相比的收益增加及集团整体开支比率 下降。(格隆汇) ...

Group 1: Regulatory Developments - The Hong Kong Monetary Authority (HKMA) has released guidelines for stablecoin issuers, which will be implemented starting August 1, 2025 [1] - Institutions interested in applying for a license are encouraged to contact the HKMA by August 31, 2025, with a deadline for applications set for September 30, 2025 [1] - Predictions suggest that major tech companies like Ant Group and JD.com may be among the first to receive licenses due to their blockchain expertise and application scenarios [1][1] Group 2: Market Performance - The Hong Kong Stock Exchange reported an average daily turnover of HKD 240.2 billion for the first half of 2025, marking a significant year-on-year increase of 118% [5] - The growth in trading volume is attributed to the expansion of the ETF mutual market and the continuous listing of new ETF products, with ETF daily turnover rising to HKD 33.8 billion, a 184% increase year-on-year [5] Group 3: Company Developments - Macau's hotel industry saw an average occupancy rate of 89.1% in the first half of 2025, an increase of 5.1 percentage points year-on-year [6] - In the first half of 2025, Huaneng International Power Co. reported a net profit of approximately RMB 9.262 billion, a year-on-year increase of 24.26% [15] - Youzan expects to achieve a net profit of approximately RMB 68 million to RMB 74 million for the six months ending June 30, 2025, compared to a net loss of RMB 4.295 million in the same period last year [13]

智通财经APP获悉，心玮医疗-B(06609)早盘涨超11%，截至发稿，涨7.78%，报59.6港元，成交额985.61 万港元。 此外，公告指出，董事会建议利用资本储备抵销亏损，但须经股东以普通决议案方式批准，而相关建议 将提呈公司将于8月29日举行的第二次临时股东大会供股东审议及通过为普通决议案。 消息面上，心玮医疗发盈喜，集团预期截至2025年6月30日止6个月取得股东应占净利润不少于人民币 4000万元，同比转亏为盈。主要由于集团的业务增长，导致与相应期间相比的收益增加及本集团整体开 支比率下降。 ...

Group 1 - Heartway Medical-B (06609.HK) expects a net profit of no less than RMB 40 million for the six months ending June 30, 2025, a significant turnaround from a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] - The anticipated profit and performance improvement are primarily due to business growth, leading to increased revenue and a decrease in overall expenditure ratio compared to the corresponding period [1] Group 2 - Baoshan International (03813.HK) expects a mid-term net profit of approximately RMB 187.6 million, a year-on-year decrease of 44.1% [2] - Baio Family Interaction (02100.HK) anticipates a mid-term profit increase of approximately 134.9% to 141.6% [2] - Skyworth Group (00751.HK) warns of an expected mid-term post-tax profit decline of about 50% year-on-year [2] Group 3 - China CNR Corporation (01766.HK) recently signed a significant contract worth approximately RMB 32.92 billion [2] - China Power (02380.HK) reported a total electricity sales volume of 11.299 million megawatt-hours in June, a year-on-year decrease of 5.04% [2]

Core Viewpoint - The company, Heartway Medical-B (06609.HK), expects to report a significant turnaround in its financial performance, projecting a net profit attributable to shareholders of no less than RMB 40 million for the six months ending June 30, 2025, compared to a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] Financial Performance - The anticipated profit and improvement in performance are primarily attributed to business growth, which has led to an increase in revenue compared to the corresponding period [1] - The overall expense ratio of the company is expected to decline, contributing to the positive financial outlook [1]

心玮医疗-B(06609.HK)发布公告，本集团预期截至2025年6月30日止6个月取得股东应占净利润不少于人 民币4000万元，较截至2024年6月30日止6个月(相应期间)取得的股东应占净亏损约人民币510万元大幅 转亏为盈。预期取得利润及业绩改善乃主要由于本集团的业务增长，导致与相应期间相比的收益增加及 本集团整体开支比率下降。 ...

董事会建议根据本公司组织章程细则、相关法律及法规利用本公司资本储备抵销其亏损。有关亏损抵销 须经股东以普通决议案方式批准，而相关建议将提呈本公司将于2025年8月29日举行的2025年第二次临 时股东大会供股东审议及通过为普通决议案。 心玮医疗-B(06609)发布公告，本集团预期截至2025年6月30日止6个月取得股东应占净利润不少于人民 币4000万元，较截至2024年6月30日止6个月(相应期间)取得的股东应占净亏损约人民币510万元大幅转 亏为盈。预期取得利润及业绩改善乃主要由于本集团的业务增长，导致与相应期间相比的收益增加及本 集团整体开支比率下降。 ...

董事会建议根据本公司组织章程细则、相关法律及法规利用本公司资本储备抵销其亏损。有关亏损抵销 须经股东以普通决议案方式批准，而相关建议将提呈本公司将于2025年8月29日举行的2025年第二次临 时股东大会供股东审议及通过为普通决议案。 智通财经APP讯，心玮医疗-B(06609)发布公告，本集团预期截至2025年6月30日止6个月取得股东应占净 利润不少于人民币4000万元，较截至2024年6月30日止6个月(相应期间)取得的股东应占净亏损约人民币 510万元大幅转亏为盈。预期取得利润及业绩改善乃主要由于本集团的业务增长，导致与相应期间相比 的收益增加及本集团整体开支比率下降。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6609） 正面盈利預告 及建議利用資本儲備抵銷虧損 本公告由上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見 上市規則）刊發。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 董事長 王國輝 正面盈利預告 本公司董事會（「董事會」）欣然通知本公司股東（「股東」）及潛在投資者，根據 對本集團截至2025年6月30日止六個月（「報告期間」）之未經審核綜合管理賬目 之初步評估及董事會現時可得資料，本集團預期錄得股東應佔 ...